BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26980332)

  • 1. Prediction of skeletal-related events in patients with non-small cell lung cancer.
    Aiba H; Kimura T; Yamagami T; Watanabe N; Sakurai H; Kimura H; Shimozaki S; Yamada S; Otsuka T
    Support Care Cancer; 2016 Aug; 24(8):3361-7. PubMed ID: 26980332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spine-specific skeletal related events and mortality in non-small cell lung cancer patients: a single-institution analysis.
    Adogwa O; Rubio DR; Buchowski JM; D'Souza A; Shlykov MA; Jennings JW
    J Neurosurg Spine; 2022 Jan; 36(1):125-132. PubMed ID: 33254136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
    Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
    J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
    Sun JM; Ahn JS; Lee S; Kim JA; Lee J; Park YH; Park HC; Ahn MJ; Ahn YC; Park K
    Lung Cancer; 2011 Jan; 71(1):89-93. PubMed ID: 20598769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
    Miyashita H; Cruz C; Smith C
    Support Care Cancer; 2021 Mar; 29(3):1629-1633. PubMed ID: 32747990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.
    da Silva GT; Bergmann A; Thuler LCS
    Support Care Cancer; 2016 Feb; 24(2):731-736. PubMed ID: 26143039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.
    Cetin K; Christiansen CF; Jacobsen JB; Nørgaard M; Sørensen HT
    Lung Cancer; 2014 Nov; 86(2):247-54. PubMed ID: 25240518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal metastases in non-small cell lung cancer: a retrospective study.
    Tsuya A; Kurata T; Tamura K; Fukuoka M
    Lung Cancer; 2007 Aug; 57(2):229-32. PubMed ID: 17451841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence and clinical impact of bone metastases in non-small cell lung cancer.
    Kuchuk M; Kuchuk I; Sabri E; Hutton B; Clemons M; Wheatley-Price P
    Lung Cancer; 2015 Aug; 89(2):197-202. PubMed ID: 26003503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
    Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
    Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
    Barlev A; Song X; Ivanov B; Setty V; Chung K
    J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
    Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
    Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
    Saito G; Ebata T; Ishiwata T; Iwasawa S; Yoshino I; Takiguchi Y; Tatsumi K
    Support Care Cancer; 2021 Jul; 29(7):4081-4088. PubMed ID: 33404803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study.
    Mizuta K; Oshiro H; Katsuki R; Tsuha Y; Aoki Y; Tome Y; Nishida K
    BMC Cancer; 2023 Oct; 23(1):999. PubMed ID: 37853409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.